Discovery of a long-acting nanocrystal formulation of INND-2201, a new co-drug of pregabalin and palmitoylethanolamide with synergistic analgesic effects

Le résumé fourni par la source

Chronic pain is a global health problem affecting approximately 30% of the adult population worldwide. Currently available painkillers often showed limited efficacy or serious adverse effects and require frequent administration to maintain therapeutic effects. To develop new long-acting analgesics with synergistic antinociceptive effects, a new co-drug INND-2201 of pregabalin and palmitoylethanolamide (PEA) was synthesized, characterized and prepared as a nanocrystal formulation. INND-2201 was slowly metabolized into pregabalin and PEA in microsomal stability test, and oral INND-2201 exhibited significant and synergistic antinociceptive effects for inflammatory and neuropathic pain with ED 50 values of 4.43 and 5.54 mg/kg, respectively. Nanocrystals (NCs) of INND-2201 were then prepared by the ball milling method with the particle size of 107.1 ± 2.7 nm. Intramuscular administration of INND-2201 NCs demonstrated prolonged pain relief lasting up to 5 days for chronic inflammatory pain in mice. Acute toxicity test, muscular irritation evaluation, rotarod test and open field test indicated that INND-2201 had a good safety profile. Taken together, INND-2201 NCs exerted long-acting analgesic effects and provided a promising strategy for the management of chronic pain. • A new co-drug INND-2201 was obtained by esterification of pregabalin with palmitoylethanolamide; • Oral INND-2201 exerted synergistic antinociceptive effects for inflammatory pain and neuropathic pain; • INND-2201 nanocrystals demonstrated prolonged pain relief lasting up to 5 days for chronic inflammatory pain in mice; • INND-2201 and INND-2201 nanocrystals hold good safety profiles in acute toxicity test or muscular irritation evaluation.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.